CORCEPT THERAPEUTICS INC (CORT)
US2183521028 - Common Stock
Overall CORT gets a fundamental rating of 7 out of 10. We evaluated CORT against 193 industry peers in the Pharmaceuticals industry. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CORT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make CORT a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
In the past 5 years CORT has always been profitable.
Each year in the past 5 years CORT had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 18.08%, CORT belongs to the best of the industry, outperforming 97.91% of the companies in the same industry.
The Return On Equity of CORT (22.20%) is better than 94.24% of its industry peers.
CORT's Return On Invested Capital of 18.79% is amongst the best of the industry. CORT outperforms 94.76% of its industry peers.
CORT had an Average Return On Invested Capital over the past 3 years of 21.81%. This is significantly below the industry average of 43.18%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.08% | ||
| ROE | 22.2% | ||
| ROIC | 18.79% |
ROA(3y)20.33%
ROA(5y)20.48%
ROE(3y)23.7%
ROE(5y)23.34%
ROIC(3y)21.81%
ROIC(5y)22.46%
1.3 Margins
CORT's Profit Margin of 22.56% is amongst the best of the industry. CORT outperforms 94.76% of its industry peers.
CORT's Profit Margin has declined in the last couple of years.
CORT has a better Operating Margin (22.81%) than 89.53% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
CORT has a better Gross Margin (98.44%) than 98.43% of its industry peers.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.81% | ||
| PM (TTM) | 22.56% | ||
| GM | 98.44% |
OM growth 3Y-15.01%
OM growth 5Y-8.99%
PM growth 3Y-9.77%
PM growth 5Y-6.02%
GM growth 3Y0.08%
GM growth 5Y0.15%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CORT is creating value.
Compared to 1 year ago, CORT has less shares outstanding
Compared to 5 years ago, CORT has less shares outstanding
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 25.06 indicates that CORT is not in any danger for bankruptcy at the moment.
CORT has a Altman-Z score of 25.06. This is amongst the best in the industry. CORT outperforms 92.67% of its industry peers.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 25.06 |
ROIC/WACC1.96
WACC9.6%
2.3 Liquidity
A Current Ratio of 3.70 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Current ratio of 3.70. This is comparable to the rest of the industry: CORT outperforms 56.54% of its industry peers.
A Quick Ratio of 3.64 indicates that CORT has no problem at all paying its short term obligations.
CORT's Quick ratio of 3.64 is in line compared to the rest of the industry. CORT outperforms 58.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
CORT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.56%, which is quite impressive.
Measured over the past 5 years, CORT shows a small growth in Earnings Per Share. The EPS has been growing by 6.00% on average per year.
Looking at the last year, CORT shows a very strong growth in Revenue. The Revenue has grown by 39.65%.
CORT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.94% yearly.
EPS 1Y (TTM)55.56%
EPS 3Y3.78%
EPS 5Y6%
EPS Q2Q%46.43%
Revenue 1Y (TTM)39.65%
Revenue growth 3Y10.88%
Revenue growth 5Y13.94%
Sales Q2Q%47.69%
3.2 Future
CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.09% yearly.
CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.39% yearly.
EPS Next Y46.02%
EPS Next 2Y37.12%
EPS Next 3Y58.77%
EPS Next 5Y49.09%
Revenue Next Year45.26%
Revenue Next 2Y30.42%
Revenue Next 3Y32.89%
Revenue Next 5Y28.39%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 40.79, which means the current valuation is very expensive for CORT.
80.10% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
CORT's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 27.20.
With a Price/Forward Earnings ratio of 28.77, CORT can be considered very expensive at the moment.
78.01% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.73, CORT is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.79 | ||
| Fwd PE | 28.77 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CORT is valued a bit cheaper than 79.06% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CORT is valued cheaply inside the industry as 80.63% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 37.79 | ||
| EV/EBITDA | 32.98 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CORT has a very decent profitability rating, which may justify a higher PE ratio.
CORT's earnings are expected to grow with 58.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.89
PEG (5Y)6.8
EPS Next 2Y37.12%
EPS Next 3Y58.77%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (12/20/2024, 8:03:39 PM)
After market: 52.55 +1.15 (+2.24%)51.4
+0.25 (+0.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners87.03%
Inst Owner Change-1.58%
Ins Owners6.48%
Ins Owner Change1.28%
Market Cap5.39B
Analysts83.64
Price Target76.4 (48.64%)
Short Float %18.39%
Short Ratio17.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)39.47%
Min EPS beat(2)36.4%
Max EPS beat(2)42.54%
EPS beat(4)4
Avg EPS beat(4)24.19%
Min EPS beat(4)6.4%
Max EPS beat(4)42.54%
EPS beat(8)6
Avg EPS beat(8)14.73%
EPS beat(12)9
Avg EPS beat(12)12.47%
EPS beat(16)12
Avg EPS beat(16)11.79%
Revenue beat(2)2
Avg Revenue beat(2)3.76%
Min Revenue beat(2)3.45%
Max Revenue beat(2)4.07%
Revenue beat(4)4
Avg Revenue beat(4)3.03%
Min Revenue beat(4)1.93%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)1.69%
Revenue beat(12)7
Avg Revenue beat(12)-0.35%
Revenue beat(16)8
Avg Revenue beat(16)-1.46%
PT rev (1m)0.4%
PT rev (3m)25.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)17.5%
EPS NY rev (1m)0%
EPS NY rev (3m)22.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)21.24%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.79 | ||
| Fwd PE | 28.77 | ||
| P/S | 8.57 | ||
| P/FCF | 37.79 | ||
| P/OCF | 37.24 | ||
| P/B | 8.43 | ||
| P/tB | 8.43 | ||
| EV/EBITDA | 32.98 |
EPS(TTM)1.26
EY2.45%
EPS(NY)1.79
Fwd EY3.48%
FCF(TTM)1.36
FCFY2.65%
OCF(TTM)1.38
OCFY2.69%
SpS6
BVpS6.1
TBVpS6.1
PEG (NY)0.89
PEG (5Y)6.8
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.08% | ||
| ROE | 22.2% | ||
| ROCE | 21.79% | ||
| ROIC | 18.79% | ||
| ROICexc | 44.52% | ||
| ROICexgc | 44.52% | ||
| OM | 22.81% | ||
| PM (TTM) | 22.56% | ||
| GM | 98.44% | ||
| FCFM | 22.67% |
ROA(3y)20.33%
ROA(5y)20.48%
ROE(3y)23.7%
ROE(5y)23.34%
ROIC(3y)21.81%
ROIC(5y)22.46%
ROICexc(3y)84.97%
ROICexc(5y)97.2%
ROICexgc(3y)84.97%
ROICexgc(5y)97.2%
ROCE(3y)25.29%
ROCE(5y)26.04%
ROICexcg growth 3Y-22.27%
ROICexcg growth 5Y-10.98%
ROICexc growth 3Y-22.27%
ROICexc growth 5Y-10.98%
OM growth 3Y-15.01%
OM growth 5Y-8.99%
PM growth 3Y-9.77%
PM growth 5Y-6.02%
GM growth 3Y0.08%
GM growth 5Y0.15%
F-Score8
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 197.92% | ||
| Cap/Sales | 0.33% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 100.13% | ||
| Profit Quality | 100.49% | ||
| Current Ratio | 3.7 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | 25.06 |
F-Score8
WACC9.6%
ROIC/WACC1.96
Cap/Depr(3y)36.26%
Cap/Depr(5y)101.19%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.19%
Profit Quality(3y)128.87%
Profit Quality(5y)134.44%
High Growth Momentum
Growth
EPS 1Y (TTM)55.56%
EPS 3Y3.78%
EPS 5Y6%
EPS Q2Q%46.43%
EPS Next Y46.02%
EPS Next 2Y37.12%
EPS Next 3Y58.77%
EPS Next 5Y49.09%
Revenue 1Y (TTM)39.65%
Revenue growth 3Y10.88%
Revenue growth 5Y13.94%
Sales Q2Q%47.69%
Revenue Next Year45.26%
Revenue Next 2Y30.42%
Revenue Next 3Y32.89%
Revenue Next 5Y28.39%
EBIT growth 1Y45.99%
EBIT growth 3Y-5.76%
EBIT growth 5Y3.69%
EBIT Next Year53.38%
EBIT Next 3Y45.42%
EBIT Next 5Y26.86%
FCF growth 1Y4.95%
FCF growth 3Y-5.59%
FCF growth 5Y1.92%
OCF growth 1Y6.09%
OCF growth 3Y-5.8%
OCF growth 5Y1.89%